Antibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14382-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#14382-1-AP, RRID:AB_2076871
- Product name
- CDT1 antibody
- Antibody type
- Polyclonal
- Description
- CDT1 antibody (Cat. #14382-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: WB, ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
Involvement of proliferation of atypical hepatocytes and CDT 1 in the liver cancer of rats administered the diethylnitrosamine.
The significance of CDT1 expression in non-cancerous and cancerous liver in cases with hepatocellular carcinoma.
Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application.
The proliferation of atypical hepatocytes and CDT1 expression in noncancerous tissue are associated with the postoperative recurrence of hepatocellular carcinoma.
Suppression of intrahepatic cholangiocarcinoma cell growth by SKI via upregulation of the CDK inhibitor p21.
CDT1 Is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.
IP(6)-assisted CSN-COP1 competition regulates a CRL4-ETV5 proteolytic checkpoint to safeguard glucose-induced insulin secretion.
Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction.
RACK1 promotes lung cancer cell growth via an MCM7/RACK1/ Akt signaling complex.
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.
Jiang J, Zhang Y, Wang J, Yang X, Ren X, Huang H, Wang J, Lu J, Zhong Y, Lin Z, Lin X, Jia Y, Lin S
PeerJ 2023;11:e16166
PeerJ 2023;11:e16166
Involvement of proliferation of atypical hepatocytes and CDT 1 in the liver cancer of rats administered the diethylnitrosamine.
Ogawa M, Masuzaki R, Kanda T, Matsumura H, Nakamura H, Yamazaki M, Shibata T, Kogure H, Moriyama M
Journal of clinical biochemistry and nutrition 2023 Sep;73(2):138-144
Journal of clinical biochemistry and nutrition 2023 Sep;73(2):138-144
The significance of CDT1 expression in non-cancerous and cancerous liver in cases with hepatocellular carcinoma.
Ogawa M, Moriyama M, Midorikawa Y, Nakamura H, Shibata T, Kuroda K, Nakayama H, Kanemaru K, Miki T, Sugitani M, Takayama T
Journal of clinical biochemistry and nutrition 2023 Nov;73(3):234-248
Journal of clinical biochemistry and nutrition 2023 Nov;73(3):234-248
Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application.
Ren X, Huang M, Weng W, Xie Y, Wu Y, Zhu S, Zhang Y, Li D, Lai J, Shen S, Lin J, Kuang M, Li X, Yu J, Xu L
Cell reports. Medicine 2023 Nov 21;4(11):101277
Cell reports. Medicine 2023 Nov 21;4(11):101277
The proliferation of atypical hepatocytes and CDT1 expression in noncancerous tissue are associated with the postoperative recurrence of hepatocellular carcinoma.
Moriyama M, Kanda T, Midorikawa Y, Matsumura H, Masuzaki R, Nakamura H, Ogawa M, Matsuoka S, Shibata T, Yamazaki M, Kuroda K, Nakayama H, Higaki T, Kanemaru K, Miki T, Sugitani M, Takayama T
Scientific reports 2022 Nov 28;12(1):20508
Scientific reports 2022 Nov 28;12(1):20508
Suppression of intrahepatic cholangiocarcinoma cell growth by SKI via upregulation of the CDK inhibitor p21.
Kawamura E, Matsubara T, Daikoku A, Deguchi S, Kinoshita M, Yuasa H, Urushima H, Odagiri N, Motoyama H, Kotani K, Kozuka R, Hagihara A, Fujii H, Uchida-Kobayashi S, Tanaka S, Takemura S, Iwaisako K, Enomoto M, Taguchi YH, Tamori A, Kubo S, Ikeda K, Kawada N
FEBS open bio 2022 Dec;12(12):2122-2135
FEBS open bio 2022 Dec;12(12):2122-2135
CDT1 Is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.
Cai C, Zhang Y, Hu X, Hu W, Yang S, Qiu H, Chu T
Frontiers in oncology 2021;11:721644
Frontiers in oncology 2021;11:721644
IP(6)-assisted CSN-COP1 competition regulates a CRL4-ETV5 proteolytic checkpoint to safeguard glucose-induced insulin secretion.
Lin H, Yan Y, Luo Y, So WY, Wei X, Zhang X, Yang X, Zhang J, Su Y, Yang X, Zhang B, Zhang K, Jiang N, Chow BKC, Han W, Wang F, Rao F
Nature communications 2021 Apr 28;12(1):2461
Nature communications 2021 Apr 28;12(1):2461
Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction.
Zhou W, Ma L, Ding L, Guo Q, He Z, Yang J, Qiao H, Li L, Yang J, Yu S, Zhao L, Wang S, Liu HM, Suo Z, Zhao W
Journal of medicinal chemistry 2019 Jun 13;62(11):5382-5403
Journal of medicinal chemistry 2019 Jun 13;62(11):5382-5403
RACK1 promotes lung cancer cell growth via an MCM7/RACK1/ Akt signaling complex.
Fei L, Ma Y, Zhang M, Liu X, Luo Y, Wang C, Zhang H, Zhang W, Han Y
Oncotarget 2017 Jun 20;8(25):40501-40513
Oncotarget 2017 Jun 20;8(25):40501-40513
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.
Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP
Nature 2010 Mar 18;464(7287):374-9
Nature 2010 Mar 18;464(7287):374-9
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The CDT1 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human CDT1. This antibody recognizes human,mouse,rat antigen. The CDT1 antibody has been validated for the following applications: ELISA, WB analysis.